Bile Acids as Modulators of Apoptosis

Hepatotoxicity: From Genomics to in vitro and in vivo Models

Volumn , Issue , 2008, Pages 391-419

  Castro, Rui E ^a   Solá, Susana ^a   Steer, Clifford J ^b   Rodrigues, Cecília M P ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cell survival and death pathways; Cholesterol homeostasis; Cytotoxic compounds; Enterohepatic circulation; Fat digestion and absorption; Fatty acids and bile acids; Hydrophobic bile acids; Negative feedback mechanism; Signaling molecules; Survival and antiapoptotic signaling

Indexed keywords

EID: 84889333062     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470516751.ch15     Document Type: Chapter

References (137)

1. Almeida OF, Conde GL, Crochemore C, Demeneix BA, Fischer D, Hassan AH, Meyer M, Holsboer F and Michaelidis TM (2000). Subtle shifts in the ratio between pro-and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 14: 779-790.
2. Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe N and Boyer JL (2002). Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 36: 49-54.
3. Barnhart BC and Peter ME (2003). The TNF receptor 1: a split personality complex. Cell 114: 148-150.
4. Bellas RE, FitzGerald MJ, Fausto N and Sonenshein GE (1997). Inhibition of NF-κB activity induces apoptosis in murine hepatocytes. Am J Pathol 151: 891-896.
5. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R and Weissberg P (1998). Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282: 290-293.
6. Berke G (1995). The CTL's kiss of death. Cell 81: 9-12.
7. Bernt C, Vennegeerts T, Beuers U and Rust C (2006). The human transcription factor AP-1 is a mediator of bile acid-induced liver cell apoptosis. Biochem Biophys Res Commun 340: 800-806.
8. Beuers U, Boyer JL and Paumgartner G (1998). Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28: 1449-1453.
9. Bird GL, Sheron N, Goka AK, Alexander GJ and Williams RS (1990). Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 112: 917-920.
10. Botla R, Spivey JR, Aguilar H, Bronk SF and Gores GJ (1995). Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 272: 930-938.
11. BourguetW, Germain P and Gronemeyer H (2000). Nuclear receptor ligand-binding domains: threedimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 21: 381-388.
12. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA and Lemasters JJ (1998a). The mitochondrial permeability transition is required for tumor necrosis factor α-mediated apoptosis and cytochrome c release. Mol Cell Biol 18: 6353-6364.
13. Bradham CA, Plumpe J, Manns MP, Brenner DA and Trautwein C (1998b). Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 275: G387-G392.
14. Broker LE, Kruyt FA and Giaccone G (2005). Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
15. Canbay A, Friedman S and Gores GJ (2004). Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39: 273-278.
16. Castro RE, Solá S, Ramalho RM, Steer CJ and Rodrigues CMP (2004). The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther 311: 845-852.
17. Castro RE, Solá S, Ma X, Ramalho RM, Kren BT, Steer CJ and Rodrigues CMP (2005). A distinct microarray gene expression profile in primary rat hepatocytes incubated with ursodeoxycholic acid. J Hepatol 42: 897-906.
18. Castro RE, Amaral JD, Solá S, Kren BT, Steer CJ and Rodrigues CMP (2007). Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes. Am J Physiol Gastrointest Liver Physiol 293: G327-G334.
19. Chiang JY, Kimmel R, Weinberger C and Stroup D (2000). Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene (CYP7A1) transcription. J Biol Chem 275: 10918-10924.
20. Datta SR, Brunet A and Greenberg ME (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
21. Davis RJ (2000). Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
22. Dent P, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S and Hylemon PB (2005a). Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology 42: 1291-1299.
23. Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW and Hylemon PB (2005b). Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol 70: 1685-1696.
24. Duan WM, Rodrigues CMP, Zhao LR, Steer CJ and Low WC (2002). Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant 11: 195-205.
25. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S and Brasitus TA (1994). Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 54: 5071-5074.
26. Fang Y, Han SI, Mitchell C, Gupta S, Studer E, Grant S, Hylemon PB and Dent P (2004). Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology 40: 961-971.
27. Faouzi S, Burckhardt BE, Hanson JC, Campe CB, Schrum LW, Rippe RA and Maher JJ (2001). Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-κB-independent, caspase-3-dependent pathway. J Biol Chem 276: 49077-49082.
28. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH and Gores GJ (1999). Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 103: 137-145.
29. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, Tallet D, del Soldato P and Morelli A (2001). NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 98: 8897-8902.
30. Garbo GM, Vicente MG, Fingar V and Kessel D (2003). Effects of ursodeoxycholic acid on photodynamic therapy in a murine tumor model. Photochem Photobiol 78: 407-410.
31. Graf D, Kurz AK, Fischer R, Reinehr R and Haussinger D (2002). Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner. Gastroenterology 122: 1411-1427.
32. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P and Korsmeyer SJ (1999). Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274: 1156-1163.
33. Guicciardi ME and Gores GJ (2005). Apoptosis: a mechanism of acute and chronic liver injury. Gut 54: 1024-1033.
34. Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr., Kliewer SA, Gonzalez FJ and Sinal CJ (2003). Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 278: 45062-45071.
35. Han SI, Studer E, Gupta S, Fang Y, Qiao L, LiW, Grant S, Hylemon PB and Dent P (2004). Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes. Hepatology 39: 456-463.
36. Hengartner MO (2000). The biochemistry of apoptosis. Nature 407: 770-776.
37. Higuchi H and Gores GJ (2003). Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 284: G734-G738.
38. Higuchi H, Bronk SF, Takikawa Y,Werneburg N, Takimoto R, El-DeiryWand Gores GJ (2001). The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 276: 38610-38618.
39. Higuchi H,Yoon JH, Grambihler A,WerneburgN, Bronk SF and Gores GJ (2003). Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem 278: 454-461.
40. Hofmann AF (2002). Cholestatic liver disease: pathophysiology and therapeutic options. Liver 22(Suppl 2): 14-19.
41. Hong H, Kohli K, Garabedian MJ and Stallcup MR (1997). GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid and vitamin D receptors. Mol Cell Biol 17: 2735-2744.
42. Howard WR, Pospisil JA, Njolito E and Noonan DJ (2000). Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol Appl Pharmacol 163: 195-202.
43. Hsu H, Xiong J and Goeddel DV (1995). The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81: 495-504.
44. Iida N, Sugiyama A, Myoubudani H, Inoue K, Sugamata M, Ihara T, Ueno Y and Tashiro F (1998). Suppression of arachidonic acid cascade-mediated apoptosis in aflatoxin B1-induced rat hepatoma cells by glucocorticoids. Carcinogenesis 19: 1191-1202.
45. Im E and Martinez JD (2004). Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 134: 483-486.
46. Jaeschke H and Lemasters JJ (2003). Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125: 1246-1257.
47. Jones BA, Rao YP, Stravitz RT and Gores GJ (1997). Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C. Am J Physiol 272: G1109-G1115.
48. Kasahara I, Saitoh K and Nakamura K (2000). Apoptosis in acute hepatic failure: histopathological study of human liver tissue using the tunel method and immunohistochemistry. J Med Dent Sci 47: 167-175.
49. Keene CD, Rodrigues CMP, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ and Low WC (2001). A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol 171: 351-360.
50. Keene CD, Rodrigues CMP, Eich T, Chhabra MS, Steer CJ and Low WC (2002). Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 99: 10671-10676.
51. Kerr JF, Wyllie AH and Currie AR (1972). Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer 26: 239-257.
52. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH and Peter ME (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588.
53. Kurose I, Higuchi H, Miura S, Saito H, Watanabe N, Hokari R, Hirokawa M, Takaishi M, Zeki S, Nakamura T, Ebinuma H, Kato S and Ishii H (1997). Oxidative stress-mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Hepatology 25: 368-378.
54. Lazaridis KN, Gores GJ and Lindor KD (2001). Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 35: 134-146.
55. Lemasters JJ (2005). Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology 129: 351-360.
56. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA and Herman B (1998). The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177-196.
57. Li YC, Wang DP and Chiang JY (1990). Regulation of cholesterol 7α-hydroxylase in the live. Cloning, sequencing, and regulation of cholesterol 7α-hydroxylase mRNA. J Biol Chem 265: 12012-12019.
58. Li S, Zhao Y, He X, Kim TH, Kuharsky DK, Rabinowich H, Chen J, Du C and Yin XM (2002). Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem 277: 26912-26920.
59. Li G, Wang S and Gelehrter TD (2003). Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor-beta action. J Biol Chem 278: 41779-41788.
60. Liedtke C, Plumpe J, Kubicka S, Bradham CA, Manns MP, Brenner DA and Trautwein C (2002). Jun kinase modulates tumor necrosis factor-dependent apoptosis in liver cells. Hepatology 36: 315-325.
61. Lim-Tio SS and Fuller PJ (1998). Intracellular signaling pathways confer specificity of transactivation by mineralocorticoid and glucocorticoid receptors. Endocrinology 139: 1653-1661.
62. Liu H, Lo CR and Czaja MJ (2002). NF-κB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 35: 772-778.
63. Loguercio C and Federico A (2003). Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 34: 1-10.
64. Madan AP and DeFranco DB (1993). Bidirectional transport of glucocorticoid receptors across the nuclear envelope. Proc Natl Acad Sci USA 90: 3588-3592.
65. Majno G and Joris I (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146: 3-15.
66. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ and Shan B (1999). Identification of a nuclear receptor for bile acids. Science 284: 1362-1365.
67. Malhi H, Gores GJ and Lemasters JJ (2006). Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology 43: S31-44.
68. Marzioni M, Francis H, Benedetti A, Ueno Y, Fava G, Venter J, Reichenbach R, Mancino MG, Summers R, Alpini G and Glaser S (2006). Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. Am J Pathol 168: 398-409.
69. Mendoza ME, Monte MJ, El-Mir MY, Badia MD and Marin JJ (2002). Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis. Clin Sci (London) 102: 143-150.
70. Mitsuyoshi H, Nakashima T, Inaba K, Ishikawa H, Nakajima Y, Sakamoto Y, Matsumoto M, Okanoue T and Kashima K (1997). Ursodeoxycholic acid enhances glucocorticoid-induced tyrosine aminotransferase-gene expression in cultured rat hepatocytes. Biochem Biophys Res Commun 240: 732-736.
71. Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, Morimoto C, Makino I and Tanaka H (2001). Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J Biol Chem 276: 47371-47378.
72. Monte MJ, Martinez-Diez MC, El-Mir MY, Mendoza ME, Bravo P, Bachs O and Marin JJ (2002). Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. J Hepatol 36: 534-542.
73. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD and Lehmann JM (1999). Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368.
74. Paumgartner G and Beuers U (2002). Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531.
75. Peter ME and Krammer PH (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10: 26-35.
76. Planey SL, Derfoul A, Steplewski A, Robertson NM and Litwack G (2002). Inhibition of glucocorticoid-induced apoptosis in 697 pre-B lymphocytes by the mineralocorticoid receptor N-terminal domain. J Biol Chem 277: 42188-42196.
77. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB and Dent P (2001). Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell 12: 2629-2645.
78. Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, Hylemon PB and Dent P (2002). Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 35: 779-789.
79. Reed JC (2000). Mechanisms of apoptosis. Am J Pathol 157: 1415-1430.
80. Reinehr R and Haussinger D (2004). Inhibition of bile salt-induced apoptosis by cyclic AMP involves serine/threonine phosphorylation of CD95. Gastroenterology 126: 249-262.
81. Reinehr R, Becker S, Hongen A and Haussinger D (2004). The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95. J Biol Chem 279: 23977-23987.
82. Reinehr R, Becker S, Keitel V, Eberle A, Grether-Beck S and Haussinger D (2005). Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 129: 2009-2031.
83. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM and Mangelsdorf DJ (2000). Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289: 1524-1529.
84. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME and Rodrigues CMP (2004). Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99: 1708-1717.
85. Ricci JE, Gottlieb RA and Green DR (2003). Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J Cell Biol 160: 65-75.
86. Roberts LR, Adjei PN and Gores GJ (1999). Cathepsins as effector proteases in hepatocyte apoptosis. Cell Biochem Biophys 30: 71-88.
87. RodriguesCMPand Steer CJ (2000). Mitochondrial membrane perturbations in cholestasis. J Hepatol 32: 135-141.
88. Rodrigues CMP, Fan G,Wong PY, Kren BT and Steer CJ (1998a). Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 4: 165-178.
89. Rodrigues CMP, Fan G, Ma X, Kren BT and Steer CJ (1998b). A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101: 2790-2799.
90. RodriguesCMP,MaX, Linehan-Stieers C, FanG, KrenBTand Steer CJ (1999). Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 6: 842-854.
91. Rodrigues CMP, Castro RE and Steer CJ (2000a). The neuroprotective characteristics of ursodeoxycholic acid and its conjugates, in Biology of Bile Acids in Heath and Disease, van Berge Henegouwen GP, Keppler D, Leuschner U and Paumgartner G (Eds), Kluwer Academic Publishers; The Netherlands, pp. 255-270.
92. Rodrigues CMP, Stieers CL, Keene CD, Ma X, Kren BT, Low WC and Steer CJ (2000b). Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem 75: 2368-2379.
93. Rodrigues CMP, Spellman SR, Solá S, Grande AW, Linehan-Stieers C, LowWC and Steer CJ (2002). Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab 22: 463-471.
94. Rodrigues CMP, Solá S, Sharpe JC, Moura JJ and Steer CJ (2003a). Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome c release in isolated mitochondria. Biochemistry 42: 3070-3080.
95. Rodrigues CMP, Solá S, Nan Z, Castro RE, Ribeiro PS, Low WC and Steer CJ (2003b). Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci USA 100: 6087-6092.
96. Russell DW and Setchell KD (1992). Bile acid biosynthesis. Biochemistry 31: 4737-4749.
97. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD and Gores GJ (2000). The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 275: 20210-20216.
98. Ryo K, KamogawaY, Ikeda I,Yamauchi K,Yonehara S, Nagata S and HayashiN (2000). Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol 95: 2047-2055.
99. Sackey FN, Hache RJ, Reich T,Kwast-Welfeld J and LefebvreYA (1996). Determinants of subcellular distribution of the glucocorticoid receptor. Mol Endocrinol 10: 1191-1205.
100. Savill J and FadokV (2000). Corpse clearance defines the meaning of cell death. Nature 407: 784-788.
101. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687.
102. Schmucker DL, Ohta M, Kanai S, Sato Y and Kitani K (1990). Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 12: 1216-1221.
103. Schoemaker MH and Moshage H (2004). Defying death: the hepatocyte's survival kit. Clin Sci (London) 107: 13-25.
104. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, Haisma HJ, Jansen PL and Moshage H (2004). Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology 39: 1563-1573.
105. Schuchmann M and Galle PR (2002). Dead or alive-NF-κB, the guardian which tips the balance. J Hepatol 36: 827-828.
106. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ and Schuetz JD (2001). Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters and cytochrome P450. J Biol Chem 276: 39411-39418.
107. Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE and Poupon R (2003). Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 38: 203-209.
108. Setchell KD, Rodrigues CMP, Clerici C, Solinas A, Morelli A, Gartung C and Boyer J (1997). Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 112: 226-235.
109. Sodeman T, Bronk SF, Roberts PJ, Miyoshi H and Gores GJ (2000). Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol 278: G992-G999.
110. Sokol RJ, Straka MS, Dahl R, Devereaux MW, Yerushalmi B, Gumpricht E, Elkins N and Everson G (2001). Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr Res 49: 519-531.
111. Solá S, Ma X, Castro RE, Kren BT, Steer CJ and Rodrigues CMP (2003a). Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor β1-induced apoptosis of rat hepatocytes. J Biol Chem 278: 48831-48838.
112. Solá S, Castro RE, Laires PA, Steer CJ and Rodrigues CMP (2003b). Tauroursodeoxycholic acid prevents amyloid-β peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med 9: 226-234.
113. Solá S, Castro RE, Kren BT, Steer CJ and Rodrigues CMP (2004). Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-β1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes. Biochemistry 43: 8429-8438.
114. Solá S, Amaral JD, Castro RE, Ramalho RM, Borralho PM, Kren BT, Tanaka H, Steer CJ and Rodrigues CMP (2005). Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes. Hepatology 42: 925-934.
115. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J,Willson TM, Koller BH and Kliewer SA (2001). The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98: 3369-3374.
116. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2: 1361-1366.
117. Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M and Trautwein C (2000). Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 119: 446-460.
118. Tanaka H and Makino I (1992). Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem Biophys Res Commun 188: 942-948.
119. Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, Sato Y and Makino I (1996). Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol 156: 1601-1608.
120. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M and Lin A (2001). Inhibition of JNK activation through NF-κB target genes. Nature 414: 313-317.
121. Tirosh O, Aronis A and Melendez JA (2003). Mitochondrial state 3 to 4 respiration transition during Fas-mediated apoptosis controls cellular redox balance and rate of cell death. Biochem Pharmacol 66: 1331-1334.
122. Trauner M, Meier PJ and Boyer JL (1999). Molecular regulation of hepatocellular transport systems in cholestasis. J Hepatol 31: 165-178.
123. Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV and Brentnall TA (2001). Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134: 89-95.
124. Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK and Brenner DA (2005). JNK mediates hepatic ischemia reperfusion injury. J Hepatol 42: 850-859.
125. Vander Heiden MG and Thompson CB (1999). Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?. Nat Cell Biol 1: E209-E216.
126. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CMP, Alfonso A, Steer CJ, Liu L, Przedborski S andWolozin B (2005). Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin and DJ-1 in Caenorhabditis elegans. J Biol Chem 280: 42655-42668.
127. Wachs FP, Krieg RC, Rodrigues CMP, Messmann H, Kullmann F, Knuchel-Clarke R, Scholmerich J, Rogler G and Schlottmann K (2005). Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor. Int J Colorectal Dis 20: 103-113.
128. Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, Ramaswamy A, Joseph L, Sitrin M, Brasitus T and Bissonnette M (2002). Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 11: 1653-1662.
129. Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin AS Jr (1998). NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683.
130. Wang H, Chen J, Hollister K, Sowers LC and Forman BM (1999). Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543-553.
131. Whitfield GK, Jurutka PW, Haussler CA and Haussler MR (1999). Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J Cell Biochem 32-33(Suppl): 110-122.
132. XieW, Radominska-Pandya A, Shi Y, Simon CM, Nelson MC, Ong ES,Waxman DJ and Evans RM (2001). An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 98: 3375-3380.
133. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, LewisDEandYoffeB (2002). Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 36: 592-601.
134. Xu Y, Jones BE, Neufeld DS and Czaja MJ (1998). Glutathione modulates rat and mouse hepatocyte sensitivity to tumor necrosis factor toxicity. Gastroenterology 115: 1229-1237.
135. Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T and Komatsu Y (1998). Inhibition by dexamethasone of transforming growth factor beta1-induced apoptosis in rat hepatoma cells: a possible association with Bcl-xL induction. Hepatology 27: 959-966.
136. Yoon JH and Gores GJ (2002). Death receptor-mediated apoptosis and the liver. J Hepatol 37: 400-410.
137. Zheng SJ, Wang P, Tsabary G and Chen YH (2004). Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113: 58-64.